Incyte has been ranked 4th on Forbes magazine’s 2016 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.
“We are very pleased to once again be included in Forbes’ list of World’s Most Innovative Companies,” said Hervé Hoppenot, Incyte’s chief executive officer. “More than half of this year’s top ten innovators are biotechnology and life sciences companies—a recognition of the major innovations seen in our industry. We at Incyte are committed to advancing science and delivering first-in-class and best-in-class medicines that will improve the lives of patients.”
Forbes’ ranking is based on the companies’ “innovation premium,” and only includes industries that are known to invest in innovation and businesses that have at least seven years of financial data and a market value greater than $10 billion.
Incyte is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.